Inventiva Shares Rise 4% Midday After Stabilization Period Ends
On Tuesday, November 25, Dijon-based biotech company Inventiva recorded a 4% increase by midday, bringing the share price to 3.64 euros. This rise follows the announcement of the end of stabilization operations linked to the public offering in the United States, which enabled the company to raise 139.3 million euros and secure its cash reserves until the first quarter of 2027.
End of Stabilization Period and Financial Impact
The stabilization period, which began on November 13, 2025, concluded on November 17 after the full exercise of the underwriters' option to subscribe to an additional 5,844,155 American Depositary Shares. This refinancing operation, conducted on the Nasdaq, raised $172.5 million through the issuance of new shares. Mid-session, the share price has increased by 4% to 3.64 euros, with a traded equity portion of 0.15%, in a Parisian market slightly up by 0.12%. Over the week, the stock has gained 3.12%, although it has fallen 6.19% over three months. However, the annual performance stands at 48.88%, significantly outperforming the CAC 40's 9.85%. This fundraising addresses a critical cash need for the biotech specializing in the treatment of MASH. The funds complement the cash reserves to finance the continuation of the phase III clinical trial for lanifibranor, its flagship drug candidate. The main results of this strategic study are expected in the second half of 2026. As of September 30, 2025, cash and cash equivalents totaled 97.6 million euros, close to the 96.6 million euros at the end of 2024.
Technical Analysis and Market Behavior
Technically, the stock is trading below its 50-day moving average, positioned at 3.94 euros, but above its 200-day average at 3.29 euros. This configuration indicates a medium-term consolidation following recent dilutive fundraising efforts. The RSI at 44 suggests a neutral territory, with no oversold or overbought signals, allowing for the continuation of the current upward movement. The Stochastic indicator is showing a buy signal, consistent with the rebound observed since the opening. Volatility remains high at 23.34% over a month, characteristic of biotechnological stocks in advanced clinical phases. The stock fluctuates between a support at 3.04 euros and a major resistance at 4 euros. The upper Bollinger band is positioned at 3.77 euros, close to the current price, suggesting a possible short-term consolidation before attempting to break through the psychological resistance of 4 euros. The positive MACD histogram at 0.05 confirms an emerging bullish divergence, while the CMF at 0.09 indicates moderate but present buying pressure in recent sessions.
Financial Outlook and Operational Expenditures
The biotech has consumed more than 40 million euros in liquidity in the first six months of the year in its research and development segment, expenses mainly related to the phase III trial. Net cash used in operating activities amounted to 76.3 million euros in the first nine months of 2025, compared to 63.7 million for the same period in 2024, an increase of 20%. The recent fundraising now ensures financial visibility until the pivotal results expected mid-2026 or 2027, a crucial step for the commercial future of lanifibranor in the treatment of this chronic liver disease affecting millions of patients. The Dijon-based company, listed simultaneously on Euronext Paris and the Nasdaq, benefits from increased exposure to American investors specialized in biotech, a sector where valuations remain high despite inherent volatility.
